Report of Foreign Issuer (6-k)
May 22 2017 - 4:07PM
Edgar (US Regulatory)
United
States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Month of May, 2017
Commission File Number: 001-35892
GW
PHARMACEUTICALS PLC
(Translation of registrant’s name
into English)
Sovereign
House
Vision
Park
Histon
Cambridge
CB24 9BZ
United
Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Notification of Interests of Senior
Officers and Connected Persons
On May 22, 2017, GW Pharmaceuticals plc
(the “Company”) announced details of new option grants to its newly appointed Chief Financial Officer and Chief Medical
Officer. The announcement is attached as Exhibit 99.1 hereto and is incorporated by reference herein. The information contained
in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, unless expressly set forth by specific reference in such a filing.
Exhibits
99.1 Company announcement
dated May 22, 2017
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
|
GW Pharmaceuticals plc
|
|
|
|
|
|
|
By:
|
/s/ Adam George
|
|
|
Name:
|
Adam George
|
|
|
Title:
|
Company Secretary
|
|
|
|
|
|
Date: May 22, 2017
|
|
|